Urology Times

Urology Times The Leading News Source for Urologists - www.UrologyTimes.com Posting Policy:
Thank you for liking the official Urology Times page. We're glad you're here.

We are committed to creating a community that encourages self-expression and mirrors the values of Urology Times including respect for the rights, dignity, and property of others. We ask all fans to do their part to help us achieve the goal. In doing that, we ask you not to post content that:
-is threatening, abusive, obscene, indecent, or objectionable.
-is deceptive, false, or misleading
-violat

es the intellectual property rights of other people
-is illegal
-references a third party website or is self-promoting spam
-is inappropriate, offensive, or hateful
We reserve the right to remove any content or block users that violate our community guidelines, or that we determine are otherwise offensive to our community. All content must also comply with Facebook's policies as well. We would be sorry to see you go, but if you change your mind and no longer want to like our page, please feel free to "unlike" our page.

What income and estate tax provisions are in the One Big Beautiful Bill Act? See insights from Allan Shen, CFP, here:
11/05/2025

What income and estate tax provisions are in the One Big Beautiful Bill Act?

See insights from Allan Shen, CFP, here:

"The OBBA includes broad and sweeping changes that will have a profound impact," writes Allan Shen, CFP.

Jen-Jane Liu, MD, discusses the emerging role and potential advantages of detalimogene voraplasmid, an investigational i...
11/05/2025

Jen-Jane Liu, MD, discusses the emerging role and potential advantages of detalimogene voraplasmid, an investigational intravesical gene therapy for NMIBC.

Liu notes that current data—showing a response rate of just over 50%—indicate that the BCG-unresponsive CIS cohort is the most appropriate initial target population.

11/04/2025

Watch our expert-led presentation to learn more about GEMTESA® (vibegron). David Staskin, MD and Kevin McVary, MD, FACS will cover key clinical insights, including data from the phase 3 COURAGE trial and provide a firsthand patient perspective. Don’t miss this opportunity to learn more! Watch now: bit.ly/4ohxzNi Please see full Prescribing Information. bit.ly/4fhyJEt

The first procedures have been completed in the ENDURE 1 study, evaluating the Optilume drug-coated balloon in patients ...
11/04/2025

The first procedures have been completed in the ENDURE 1 study, evaluating the Optilume drug-coated balloon in patients with benign ureteric strictures.

The ENDURE 1 study plans to enroll up to 60 patients with benign ureteric strictures.

The FDA has approved fosfomycin for adult patients with complicated urinary tract infections, including acute pyelonephr...
11/04/2025

The FDA has approved fosfomycin for adult patients with complicated urinary tract infections, including acute pyelonephritis.

The approval is supported by the phase 2/3 ZEUS trial.

Take a look through last month's key FDA decisions in urology with our latest regulatory recap! Sign up now to view🔓:
11/03/2025

Take a look through last month's key FDA decisions in urology with our latest regulatory recap!

Sign up now to view🔓:

A recap of the FDA submissions and regulatory decisions in urology from October 2025.

No tricks here—just timely takes on all things urology. 💧🎃Happy Halloween from Urology Times!
10/31/2025

No tricks here—just timely takes on all things urology. 💧🎃
Happy Halloween from Urology Times!

Petros Grivas, MD, PhD, recaps key bladder cancer data from ESMO 2025.
10/29/2025

Petros Grivas, MD, PhD, recaps key bladder cancer data from ESMO 2025.

Petros Grivas, MD, PhD, highlights notable trial readouts across NMIBC, MIBC, and urothelial carcinoma.

The FDA has granted breakthrough device designation to the Avvio Enhanced Lithotripsy System for ureteral stones.
10/29/2025

The FDA has granted breakthrough device designation to the Avvio Enhanced Lithotripsy System for ureteral stones.

Avvio Medical plans to submit a de novo application for clearance of the device in early 2026.

The LITESPARK-022 trial has met its primary end point, demonstrating that belzutifan plus pembrolizumab significantly im...
10/28/2025

The LITESPARK-022 trial has met its primary end point, demonstrating that belzutifan plus pembrolizumab significantly improved disease-free survival in patients with ccRCC post-nephrectomy.

Merck plans to share these data with regulatory authorities worldwide.

Topline results from LITESPARK-011: Belzutifan plus lenvatinib significantly improved PFS vs cabozantinib in patients wi...
10/28/2025

Topline results from LITESPARK-011: Belzutifan plus lenvatinib significantly improved PFS vs cabozantinib in patients with locally advanced or metastatic ccRCC.

The phase 3 LITESPARK-011 trial has met its primary end point.

CMS has issued a permanent J code for mitomycin for intravesical solution for LG-IR-NMIBC, which will be effective Janua...
10/27/2025

CMS has issued a permanent J code for mitomycin for intravesical solution for LG-IR-NMIBC, which will be effective January 1, 2026.

The code, J9282, will be effective on January 1, 2026.

Address

24950 Country Club Boulevard, Ste 200
North Olmsted, OH
44070

Alerts

Be the first to know and let us send you an email when Urology Times posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Urology Times:

Share